www.carbogen-amcis.com/sterile-drug-product-cdmo

The contents page for Autumn 2025!

https://www.aaps.org/pharmsci/annual-meeting

As the days become shorter again, and the weather cools down after a long summer, it’s the perfect time for reflecting on the year’s subjects of interest and musing about how these might be developed in the future.

https://ehpawards.com/

IPT highlights some of the most recent exciting advancements in pharmaceutical manufacturing

As novel biologics reshape the therapeutic landscape, more advanced analytics are essential. Single-particle technologies can help fill this gap, delivering faster, clearer insights and supporting the next generation of advanced therapies

What is super-resolution microscopy and how is it accelerating progress across the imaging sector?

How is low voltage electron microscopy revolutionising the electron microscopy landscape – making the practice more accessible in pharma labs?

Massive sequencing, or next-generation sequencing, has opened the door to the fascinating world of genetics, and the secret on how to use this powerful tool most effectively hinges on the starting point: the sample

SPOTLIGHT: Bill Supplee at Natoli Engineering discusses the best ways to ensure tablet density uniformity in pharma products

What are eight compelling reasons why manufacturers should prioritise the use of advanced contamination detection systems in their operations?

In biologics development, clone selection is not just a technical milestone, it’s a strategic decision with far-reaching clinical and commercial implications. How can thoughtful clone selection – integrated with developability and manufacturability assessments – accelerate speed to clinic while safeguarding long-term success?

SPOTLIGHT: How CARBOGEN AMCIS supports complex molecules and challenging formulations from early development to commercialisation

Biocatalysis is enhancing complex molecule process development. By merging the power of enzymes with chemical synthesis, scientists and manufacturers are addressing long-standing challenges in stereoselectivity, route complexity and sustainability

How will innovative human-centred in vitro testing strategies contribute to accelerating the delivery of safer and more effective therapies to patients without, or with minimal, use of animal models?

How are recent advances in proteomics, such as artificial intelligence and machine learning, transforming drug discovery and development?

Should viral clearance studies be required for genetically engineered viral vectors and viral vector-derived products?

What is single-stranded DNA and why is it a viable viral vector alternative?

Artificial intelligence-powered de novo protein design is opening new pathways in biologics discovery, allowing researchers to create synthetic proteins beyond nature’s existing repertoire

https://posummit.com/

How is artificial intelligence changing the way drug discovery and development is enacted across the sector, yielding not only impressive potential, but also clinically validated pharma products?

How is artificial intelligence, when delivered through software as a service platforms, unlocking real business outcomes for pharmaceutical manufacturers, from faster batch release and smarter investigations to smoother tech transfers and enterprise-wide compliance?

How is the industry translating the potential of automated technologies into practical, flexible and scalable workflows that address the real-world challenges of modern laboratories, ensuring that innovation delivers measurable scientific and operational gains?

IPT Autumn 2025 events page

www.flypharmaeurope.com

natoli.com/fastlok